Vollständiger Abstract
Worum geht es in dieser Arbeit?
A 67-year-old man with rising PSA and palpable prostate lesion underwent prostate MRI, which showed a large PI-RADS 5 lesion confirmed on biopsy as Gleason score 9 (4+5), grade group 5, prostate cancer. 18 F-DCFPyL PET/CT scan for initial stage showed no significant PSMA avidity in the prostate lesion. 18 F-fluciclovine was obtained for off-label disease staging and management guidance. The high Gleason score prostate lesion showed intense 18 F-fluciclovine avidity. High expression of amino acid transporters and low PSMA expression was confirmed by immunohistochemistry. This case showcases a non-PSMA-avid primary prostate cancer with intense 18 F-fluciclovine, demonstrating the potential of 18 F-fluciclovine PET/CT as an off-label alternative in the uncommon primary prostate cancer without significant PSMA expression.
Bibliografischer Nachweis
Publikationsdaten
- Autor:innen
- Ismaheel O. Lawal, Lara R. Harik, Akshay S. Bedmutha, Sagar A. Patel, Ashesh B. Jani, David M. Schuster
- Quelle
- Clinical Nuclear Medicine
- Publikation
- 2026-01-01
- Band / Ausgabe
- Nicht angegeben
- Seiten
- Nicht angegeben
- ISSN / ISBN
- 0363-9762, 1536-0229
- Zitationen
- 0 laut Crossref
- Referenzen
- 0 hinterlegt
Zitieren
Zitierfähiger Nachweis
Ismaheel O. Lawal, Lara R. Harik, Akshay S. Bedmutha, Sagar A. Patel, Ashesh B. Jani, David M. Schuster (2026). 18F-fluciclovine PET Imaging of Non-PSMA Expressing High-risk Primary Prostate Cancer. Clinical Nuclear Medicine. https://doi.org/10.1097/rlu.0000000000006659